| 1 | Feasibility of sentinel lymph node biopsy omission after integration of ^(18)F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial显示文摘Objective:Sentinel lymph node biopsy(SLNB)is currently the standard of care in clinically node negative(cN0)breast cancer.The present study aimed to evaluate the negative predictive value(NPV)of 18F-FDG dedicated lymph node positron emission tomography(LymphPET)in cN0 patients.Methods:This was a prospective phase II trial divided into 2 stages(NCT04072653).In the first stage,cN0 patients underwent axillary LymphPET followed by SLNB.In the second stage,SLNB was omitted in patients with a negative preoperative axillary assessment after integration of LymphPET.Here,we report the results of the first stage.The primary outcome was the NPV of LymphPET to detect macrometastasis of lymph nodes(LN-macro).Results:A total of 189 patients with invasive breast cancer underwent LymphPET followed by surgery with definitive pathological reports.Forty patients had LN-macro,and 16 patients had only lymph node micrometastasis.Of the 131 patients with a negative LymphPET result,16 patients had LN-macro,and the NPV was 87.8%.After combined axillary imaging evaluation with ultrasound and LymphPET,100 patients were found to be both LymphPET and ultrasound negative,9 patients had LN-macro,and the NPV was 91%.Conclusions:LymphPET can be used to screen patients to potentially avoid SLNB,with an NPV>90%.The second stage of the SOAPET trial is ongoing to confirm the safety of omission of SLNB according to preoperational axillary evaluation integrating LymphPET. | Junjie Li Jingyi Cheng Guangyu Liu Yifeng Hou Genghong Di Benglong Yang Yizhou Jiang Liang Huang Feilin Qu Sheng Chen Yan Wang Keda Yu Zhimin Shao | 2022 | Cancer Biology & Medicine2022，19，7： | 1 |
| 2 | A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score显示文摘Objective: The indication of adjuvant chemotherapy recommendation(ACR) in breast cancer patients with intermediate recurrence score(RS) is controversial. This study investigated the relationship between routine clinicopathological indicators and ACR, and established a nomogram for predicting the probability of ACR in this subset of patients.Methods: Data for a total of 504 consecutive patients with intermediate RS from January 2014 to December2016 were retrospectively reviewed. A nomogram was constructed using a multivariate logistic regression model based on data from a training set(378 cases) and validated in an independent validation set(126 cases). A Youdenderived cut-off value was assigned to the nomogram for accuracy evaluation.Results: The multivariate logistic regression analysis identified that age, histological grade, tumor size, lymph node(LN) status, molecular subtype, and RS were independent predictors of ACR. A nomogram based on these predictors performed well. The P value of the Hosmer-Lemeshow test for the prediction model was 0.286. The area under the curve(AUC) values were 0.905 [95% confidence interval(95% CI): 0.876–0.934] and 0.883(95%CI: 0.824–0.942) in the training and validation sets, respectively. The accuracies of the nomogram for ACR were84.4% in the training set and 82.1% in the validation set.Conclusions: We developed a nomogram to predict the probability of ACR in breast cancer patients with intermediate RS. This model may aid the individual risk assessment and guide treatment decisions in clinical practice. | Feilin Qu Xiaosong Chen Xiaochun Fei Lin Lin Weiqi Gao Yu Zong Jiayi Wu Ou Huang Jianrong He Li Zhu Weiguo Chen Yafen Li Kunwei Shen | 2018 | Chinese Journal of Cancer Research2018，30，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员